evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

8 questions · 8 findings · 5 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 6 · 75%Moderate 1 · 12.5%High 0 · 0%

Remdesivir and standard care vs placebo or usual care

Serious adverse events at up to day 28 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).

1 finding from 1 review

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).

1 finding from 1 review

Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment)

Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures

The review found no eligible studies for this question.

1 finding from 1 review

Hyperimmune immunoglobulin from human plasma vs saline placebo

Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19

Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).

1 finding from 1 review